Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

April 30, 2012

Conditions
Melanoma (Skin)
Interventions
DRUG

carboplatin

AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal

DRUG

paclitaxel

100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal

DRUG

temozolomide

150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks

Trial Locations (1)

55905

Mayo Clinic Cancer Center, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER